Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...